Investigational New Drugs

The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

A phase I study of the safety and tolerability of VLX an Iron Chelator, in patients with refractory advanced solid tumors

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion

CUDC- a dual HDAC and PI3K inhibitor, reverses platinum drug resistance

A phase I trial to determine safety and pharmacokinetics of ASLAN an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Phase I dose escalation study of NMS-128 an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-beta VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer